Related Experiment Video
Updated: Aug 31, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy
Michelle D Winthrop1, Sally J DeNardo, Huguette Albrecht
1University of California Davis Medical Center, Sacramento, California 95816, USA.
Purpose:
The selection and characterization of anti-MUC-1 single-chain antibody fragments (scFv) is a first step toward the construction of new anticancer molecules designed for optimal blood clearance and tumor penetration. The mucin MUC-1 was chosen as an antigen because it is abundantly expressed on epithelial cancers in an aberrantly glycosylated form, making it structurally and antigenically distinct from MUC-1 expressed on normal cells.
Experimental Design:
A previously constructed anti-MUC-1 phage display library from hyperimmunized mice, with 5 x 10(5) calculated variants, was screened for the selection of anti-MUC-1 scFvs. Selection criteria were high binding to a MUC-1 peptide containing 4 tandem repeats of 20 amino acids and to MUC-1-positive MCF-7 (human breast cancer) cell lysates in ELISA.
Results:
Six anti-MUC-1 scFv clones were selected and characterized. Nucleotide sequencing showed that four of them were full length scFv genes (variable heavy chain + variable light chain), whereas the remaining two contained either a variable heavy chain or a variable light chain alone. Their binding affinities (K(a)) range between 8 x 10(7) and 10(9) M(-1). Immunohistopathology demonstrated reactivity with breast cancer cells (MCF-7 and BT20) and human breast biopsy tissue. Molecular modeling revealed high structural similarity of the anti-MUC-1 scFvs with the X-ray-determined structure of the anti-CEA scFv (MFE-23).
Conclusions:
In vitro antigen binding was demonstrated for the selected anti-MUC-1 scFvs. The binding affinities of these scFvs are in a promising range for efficient in vivo antigen binding. These anti-MUC-1 scFvs will be evaluated as antigen-binding modules in new multifunctional agents for the detection and therapy of cancer.
Insights
Researchers selected and characterized anti-MUC-1 single-chain antibody fragments (scFv) for cancer therapy. These scFvs show promising binding affinities for MUC-1, a cancer-associated antigen, paving the way for new anticancer agents.
Area of Science:
- Biotechnology
- Immunology
- Oncology
Background:
- Mucin 1 (MUC-1) is aberrantly glycosylated and overexpressed on epithelial cancers.
- This distinct MUC-1 form serves as a potential target for cancer detection and therapy.
- Anti-MUC-1 single-chain antibody fragments (scFv) are being developed for targeted anticancer agents.
Purpose of the Study:
- To select and characterize anti-MUC-1 scFvs for potential use in novel anticancer molecules.
- To develop scFvs with optimal blood clearance and tumor penetration properties.
- To identify scFvs that bind specifically to the aberrant MUC-1 expressed on cancer cells.
Main Methods:
- Screening of a phage display library containing anti-MUC-1 scFvs.
- Selection based on binding affinity to MUC-1 peptide and cancer cell lysates via ELISA.
- Characterization using nucleotide sequencing, binding affinity assays, immunohistopathology, and molecular modeling.
Main Results:
- Six anti-MUC-1 scFv clones were successfully selected and characterized.
- Four clones contained full-length scFv genes; two contained partial genes.
- Binding affinities ranged from 8 x 10(7) to 10(9) M(-1), with demonstrated reactivity to breast cancer cells and tissues.
Conclusions:
- Selected anti-MUC-1 scFvs exhibit promising in vitro antigen binding capabilities.
- The demonstrated binding affinities suggest potential for effective in vivo targeting.
- These scFvs are suitable for evaluation as key components in new cancer detection and therapy agents.
More Related Videos
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013